SINTX Receives Notice of Allowance for United States Patent Application for Silicon Nitride-Functionalized Zirconia-Toughened Alumina Ceramic Biomaterial
SINTX Technologies (NASDAQ: SINT) has received a Notice of Allowance from the USPTO for a patent application covering novel methods of bonding bioactive silicon nitride to zirconia-toughened alumina (ZTA) surfaces. This innovation aims to enhance ZTA's biological properties, improving osseointegration and resistance to bacterial colonization.
The company, the only FDA-registered producer of implantable silicon nitride, has developed a particulate form that can be used in composites and coatings. This allows SINTX to upgrade existing devices and expand silicon nitride's applications to metallic and polymeric substrates.
SINTX's intellectual property portfolio now includes 16 issued U.S. patents and 84 pending worldwide patent applications, reinforcing its position in medical device biomaterial manufacturing.
SINTX Technologies (NASDAQ: SINT) ha ricevuto un Avviso di Concessione dal USPTO per un'applicazione di brevetto che copre metodi innovativi di legame del nitruro di silicio bioattivo alle superfici in allumina rinforzata con zirconio (ZTA). Questa innovazione mira a migliorare le proprietà biologiche della ZTA, favorendo l'osseointegrazione e la resistenza alla colonizzazione batterica.
L'azienda, unico produttore registrato dalla FDA di nitruro di silicio impiantabile, ha sviluppato una forma particellare che può essere utilizzata in compositi e rivestimenti. Questo consente a SINTX di aggiornare i dispositivi esistenti ed espandere le applicazioni del nitruro di silicio a substrati metallici e polimerici.
Il portafoglio di proprietà intellettuale di SINTX ora include 16 brevetti statunitensi concessi e 84 domande di brevetto pendenti a livello mondiale, rafforzando la sua posizione nella produzione di biomateriali per dispositivi medici.
SINTX Technologies (NASDAQ: SINT) ha recibido un Aviso de Concesión del USPTO para una solicitud de patente que cubre métodos novedosos de unión de nitruro de silicio bioactivo a superficies de alúmina reforzada con zirconio (ZTA). Esta innovación tiene como objetivo mejorar las propiedades biológicas de la ZTA, mejorando la oseointegración y la resistencia a la colonización bacteriana.
La compañía, el único productor registrado por la FDA de nitruro de silicio implantable, ha desarrollado una forma particulada que puede ser utilizada en compuestos y recubrimientos. Esto permite a SINTX actualizar los dispositivos existentes y expandir las aplicaciones del nitruro de silicio a sustratos metálicos y poliméricos.
El portafolio de propiedad intelectual de SINTX ahora incluye 16 patentes estadounidenses emitidas y 84 solicitudes de patentes pendientes a nivel mundial, reforzando su posición en la fabricación de biomateriales para dispositivos médicos.
SINTX Technologies (NASDAQ: SINT)는 USPTO로부터 생물활성 질화 규소를 지르코니아 강화 알루미나(ZTA) 표면에 결합하는 새로운 방법을 다룬 특허 출원에 대한 허가 통지를 받았습니다. 이 혁신은 ZTA의 생물학적 특성을 향상시켜 골융합 및 세균 집락 형성에 대한 저항력을 개선하는 것을 목표로 합니다.
FDA에 등록된 유일한 임플란트용 질화 규소 생산업체인 이 회사는 복합재 및 코팅에서 사용될 수 있는 입자 형태를 개발했습니다. 이는 SINTX가 기존 장치를 업그레이드하고 금속 및 폴리머 기판에 질화 규소의 응용을 확장할 수 있게 합니다.
SINTX의 지적 재산 포트폴리오는 현재 16개의 미국 특허와 전 세계적으로 84개의 특허 출원 중인 내용을 포함하고 있어 의료 기기 생체 재료 제조에서의 입지를 강화하고 있습니다.
SINTX Technologies (NASDAQ: SINT) a reçu un Avis de Concession de l'USPTO pour une demande de brevet couvrant de nouvelles méthodes de liaison du nitrure de silicium bioactif aux surfaces de zirconia renforcé d'alumine (ZTA). Cette innovation vise à améliorer les propriétés biologiques de la ZTA, favorisant l'osseointegration et la résistance à la colonisation bactérienne.
L'entreprise, le seul producteur de nitrure de silicium implantable enregistré par la FDA, a développé une forme particulaire pouvant être utilisée dans des composés et des revêtements. Cela permet à SINTX de mettre à niveau les dispositifs existants et d'étendre les applications du nitrure de silicium aux substrats métalliques et polymériques.
Le portefeuille de propriété intellectuelle de SINTX comprend désormais 16 brevets américains délivrés et 84 demandes de brevet en attente dans le monde entier, renforçant ainsi sa position dans la fabrication de biomatériaux pour dispositifs médicaux.
SINTX Technologies (NASDAQ: SINT) hat eine Mitteilung über die Genehmigung vom USPTO für einen Patentantrag erhalten, der neuartige Methoden zum Verbinden von bioaktivem Siliziumnitrid mit zirkoniaverstärktem Aluminiumoxid (ZTA) abdeckt. Diese Innovation zielt darauf ab, die biologischen Eigenschaften von ZTA zu verbessern, die Osseointegration zu fördern und die Resistenz gegen bakterielle Besiedlung zu erhöhen.
Das Unternehmen, der einzige von der FDA registrierte Hersteller von implantierbarem Siliziumnitrid, hat eine Partikelvariante entwickelt, die in Verbundwerkstoffen und Beschichtungen verwendet werden kann. Dies ermöglicht es SINTX, bestehende Geräte aufzurüsten und die Anwendungen von Siliziumnitrid auf metallische und polymerartige Substrate auszudehnen.
Das geistige Eigentum von SINTX umfasst jetzt 16 erteilte US-Patente und 84 weltweit anhängige Patentanträge, was seine Position in der Herstellung von Biomaterialien für medizinische Geräte stärkt.
- Received Notice of Allowance for a new patent application, strengthening intellectual property portfolio
- Developed particulate form of silicon nitride for use in composites and coatings
- Potential to upgrade existing medical devices with silicon nitride coating
- Expanding applications of silicon nitride to metallic and polymeric substrates
- Currently the only FDA-registered producer of implantable silicon nitride
- None.
This patent allowance for SINTX's silicon nitride-functionalized zirconia-toughened alumina (ZTA) ceramic biomaterial is a significant technological advancement in the field of medical implants. The innovation combines the bioactive properties of silicon nitride with the mechanical strength of ZTA, potentially enhancing osseointegration and bacterial resistance in implants.
This development could lead to improved patient outcomes in orthopedic and dental applications, where implant integration and infection prevention are crucial. However, it's important to note that while promising, the commercial impact remains uncertain until clinical trials demonstrate real-world efficacy and safety.
From an investor's perspective, this patent strengthens SINTX's competitive position in the biomaterials market, but revenue generation from this technology may still be years away.
While the patent allowance is a positive development for SINTX Technologies, its immediate financial impact is likely . As the only FDA-registered producer of implantable silicon nitride, SINTX has a unique market position, but the company's ability to monetize this innovation remains to be seen.
Investors should consider that R&D costs for bringing this technology to market could be substantial and the timeline for commercialization is uncertain. The potential for licensing or partnerships could provide future revenue streams, but these are speculative at this point.
SINTX's stock price may see a short-term boost from this news, but long-term value will depend on successful product development and market adoption. The company's financial health and burn rate should be closely monitored as it pursues commercialization of this technology.
Salt Lake City, Utah, Sept. 09, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”) a leading innovator in ceramic manufacturing, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application no. 17/634,141 entitled "Methods of Surface Functionalization of Zirconia-Toughed Alumina with Silicon Nitride Ceramic.” This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.
This patent allowance underscores the Company’s commitment to advancing the development of advanced ceramic for biomaterial applications, protecting its intellectual property, and delivering innovative solutions to its customers.
The patent covers novel methods of bonding bioactive silicon nitride or mixtures of silicon nitride and bioactive glass to zirconia-toughened alumina (ZTA) and similar material surfaces. This invention is designed to impart silicon nitride’s beneficial biomedical properties, namely improved osseointegration and resistance to bacterial colonization, to relatively biologically inert ZTA substrates, positioning SINTX at the forefront of medical device biomaterial manufacturing.
“Our patent allowance marks a significant milestone for our patent portfolio and the development of proprietary biomaterials” said Eric K. Olson, President and CEO of SINTX. “This innovation reinforces our leadership in innovative medical device platforms and demonstrates our ongoing commitment to developing cutting-edge solutions, transformative technologies, and development of commercial products that benefit our customers and the broader market.”
SINTX, currently the only FDA-registered producer of implantable silicon nitride, in addition to its monolithic ceramic implantable device offerings, has recently developed a particulate form of its silicon nitride that can be used in composites and coatings. When compounded with or applied to the surface of conventional inert biomaterials, silicon nitride’s improved osseointegration and resistance to bacterial colonization can be conferred to the resulting device. Another benefit of the coating method is that it allows for potential refinishing of existing devices to upgrade their functionality. Other filings in progress protect similar approaches to applying silicon nitride to metallic and polymeric substrates as part of SINTX’s broader strategy of expanding the applications where silicon nitride’s benefits can be realized.
With this allowance, SINTX continues to build a robust intellectual property portfolio, which now includes 16 issued patents in the United States with an additional 84 pending patent applications in Worldwide.
About SINTX Technologies, Inc.
SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter into new markets. The Company has manufacturing and R&D facilities in Utah and Maryland.
For more information on SINTX Technologies or its materials platform, visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy,” "future," "likely," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding advancing the development of advanced ceramic for biomaterial applications, delivering innovative solutions to our customers, and the potential to pursue growth opportunities and explore strategic opportunities.
Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. A discussion of risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 27, 2024, and in SINTX’s other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law.
Business and Media Inquiries for SINTX:
SINTX Technologies
801.839.3502
IR@sintx.com
FAQ
What is the latest patent allowance for SINTX Technologies (SINT)?
How many patents does SINTX Technologies (SINT) currently hold?
What are the key benefits of SINTX's (SINT) silicon nitride technology?
How is SINTX Technologies (SINT) expanding the applications of its silicon nitride technology?
